Mankind Pharma Q1 results: Profit rises 10% to ₹543 cr; revenue up 12%
The revenue from domestic business grew 9% YoY to ₹2,634 cr in Q1 FY25, while exports rose 62% YoY to ₹259 cr
The revenue from domestic business grew 9% YoY to ₹2,634 cr in Q1 FY25, while exports rose 62% YoY to ₹259 cr
Mankind Pharma has reported 19.4% YoY rise in profit at ₹501.03 cr in Q2 FY24, while revenue from operations jumped 11.6% to ₹2,708.10 cr.
The pharma major reported 66% YoY growth in net profit at ₹494 crore, while sales rose 18% YoY to ₹2,579 crore in Q1FY24.
The portion reserved for QIBs was subscribed over 49 times, while quota for NIIs and retail investors were booked 3.8% times and 0.9 times, respectively.
The IPO of the country’s fourth largest pharma company by domestic sales comprises an offer for the sale of 4 crore equity shares by the promoters and existing investors.